Talimogene laherparepvec (T-VEC) is an oncolytic virus approved for the treatment of patients with recurrent melanoma. Now, a recent study in patients with primary cutaneous B cell lymphoma confirms prior results in melanoma and reveals new mechanisms of action. Herein, we discuss these findings and their implications for expanding the role of oncolytic viruses.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy Open Access 19 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kaufman, H. L. et al. Oncolytic viruses: a new class of immunotherapy. Nat. Rev. Drug Disc. 18, 642–662 (2015).
Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).
Andtbacka, R. H. et al. Patterns of clinical response with Talimogene laherparepvec in patients with melanoma treated in the OPTiM Phase III clinical trial. Ann. Surg. Oncol. 23, 4169–4177 (2016).
Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIC and IV melanoma. Ann. Surg. Oncol. 17, 718–730 (2010).
Macedo, N. et al. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer. 8, e001486 (2020).
Ramelyte, E. et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell https://doi.org/10.1016/j.ccell.2020.12.022 (2021).
Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014).
Acknowledgements
The authors wish to thank G. Iodice for helpful conversations and review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.L.K. is an employee of Immuneering Corp. D.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Kaufman, H.L., Maciorowski, D. Advancing oncolytic virus therapy by understanding the biology. Nat Rev Clin Oncol 18, 197–198 (2021). https://doi.org/10.1038/s41571-021-00490-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00490-4
This article is cited by
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy (2022)